Trial · NCT07877493
Psychological Support for Chronic Migraine Patients Treated With Anti-CGRP (Anti-Calcitonin Gene-Related Peptide ) Monoclonal Antibodies
NCT07877493, Not yet recruiting, Central Hospital, Nancy, France
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Psychological Support for Chronic Migraine Patients Treated With Anti-CGRP (Anti-Calcitonin Gene-Related Peptide ) Monoclonal Antibodies. Trials, record NCT07877493. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07877493
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Psychological Support for Chronic Migraine Patients Treated With Anti-CGRP (Anti-Calcitonin Gene-Related Peptide ) Monoclonal Antibodies
- NCT number
- NCT07877493
- Status
- Not yet recruiting
- Enrollment
- 30 participants, estimated
- Lead sponsor
- Central Hospital, Nancy, France
- Conditions
- Chronic Migraine Headache, Psychologic Adaptation
- First posted
- 2026-10-16
- Last updated
- 2026-10-16
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hospital Anxiety and Depression Scale (HADS) total, anxiety, and depression scores | From baseline (first anti-CGRP infusion) to 12 months | • Psychological distress assessed using the Hospital Anxiety and Depression Scale (HADS). The scale includes a total score and two subscales: anxiety (HADS-A) and depression (HADS-D). Scores range from 0 to 21 for each subscale, with higher scores indicating greater anxiety or depressive symptoms. Participants are assessed at baseline (T0) and at 12 months (T1). Changes in HADS total score and/or HADS-A and HADS-D scores will be compared between participants reporting marked improvement of migraine and those reporting no perceived treatment efficacy.The total HADS score ranges from 0 to 42, with higher scores indicating greater overall psychological distress. |
| Secondary | Headache impact measured with the Headache Impact Test-6 (HIT-6) | From baseline (first anti-CGRP infusion) to 12 months | • The Headache Impact Test-6 (HIT-6) assesses the impact of headaches on daily functioning. Scores range from 36 to 78, with higher scores indicating a greater impact of headache on quality of life. Assessments are performed at baseline (T0) and 12 months (T1). |
| Secondary | Migraine-related disability measured with the Migraine Disability Assessment Scale (MIDAS) | From baseline (first anti-CGRP infusion) to 12 months | The Migraine Disability Assessment Scale (MIDAS) evaluates migraine-related disability. Scores range from 0 to 270, with higher scores indicating greater migraine-related disability. Assessments are performed at baseline (T0) and 12 months after treatment initiation (T1). |
| Secondary | Themes identified during psychological interviews | Baseline (T0) and 12 months (T1) | Semi-structured psychological interviews conducted at baseline (T0) and 12 months (T1) wille be reviewed using thematic analysis. Recurring themes related to participants 'experiences of anti-CGRP monoclonal antibody treatment will be identified from interview notes and reported descriptively. |
| Secondary | Changes in occupational, social, and leisure activities | Baseline (T0) and 12 months (T1) | Qualitative assessment of changes in occupational functioning, social participation, and leisure activities reported during psychological interviews between baseline (T0) and 12 months (T1). |
| Secondary | Coping strategies reported during psychological interviews | Baseline (T0) and 12 months (T1) | Qualitative evaluation of coping strategies used by participants in relation to chronic migraine and its treatment, identified through semi-structured psychological interviews conducted at baseline (T0) and 12 months (T1). |
| Secondary | Self-reported need for additional psychological support | Baseline (T0) and 12 months (T1) | Participants report whether additional psychological support is needed during the study period. Information is collected through psychological interviews at baseline (T0) and 12 months (T1). |
| Secondary | Presence of psychotraumatic experiences reported during psychological interviews | Baseline (T0) and 12 months (T1) | Identification of current or past psychotraumatic experiences reported by participants during semi-structured psychological interviews conducted at baseline (T0) and 12 months (T1). Information documented in interview notes will be reviewed qualitatively and reported descriptively. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07877493
GET https://conductscience.org/api/trials/v1/NCT07877493/registered